MedTrace Logo

Optimizing Medication Management for Mothers With Depression

NCT02519790 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 88

Last updated 2021-11-17

No results posted yet for this study

Summary

The purpose of this study is to explore the way the antidepressant concentration (amount of medication) in the blood changes due to the physiological changes in the body (i.e., changes in metabolism, hormones and body fluid) during pregnancy and postpartum and the impact of genetic factors on the degree of these changes. Changes in antidepressant concentration are important to monitor, as decreases in antidepressant concentration may lead to less than therapeutic drug levels, which may cause an increase in mood symptoms or recurrence of depressive episodes. Increases in antidepressant concentration have the potential to lead to increased side effects. The study team is hoping to better understand the course of these changes across pregnancy and postpartum and how an individual's genetic makeup impacts these changes with the goal of developing guidelines to optimize antidepressant treatment of pregnant women.

Conditions

Sponsors & Collaborators

  • University of Pittsburgh

    collaborator OTHER

  • The University of Texas Medical Branch, Galveston

    collaborator OTHER

  • Marshfield Clinic

    collaborator UNKNOWN

  • Northwestern University

    lead OTHER

Principal Investigators

  • Katherine L. Wisner, M.D., M.S. · Northwestern University

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2020-12-31
Completion
2021-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02519790 on ClinicalTrials.gov